Quotient Sciences

First-in-human trials are an opportunity to learn, adapt and make stronger development decisions. By integrating formulation, manufacturing and clinical testing, Quotient Sciences Translational Pharmaceutics® helps sponsors respond proactively to emerging human data and build a clearer path forward for their drug program. Sponsors who choose Translational Pharmaceutics® see an average 19% improved success rate in reaching Phase 2, compared to conventional methods.

Drug development is more efficient when formulation, manufacturing and clinical decisions are integrated. Translational Pharmaceutics® creates one continuous data thread across development, allowing clinical results to inform your drug product formulation decisions. The result is a more agile path forward: Fewer handoffs and better-informed decisions advance your molecule through first-in-human and to a Phase 2 milestone 8-12 months faster.

Complex formulation problems often lead to slow development decisions. Quotient Sciences Translational Pharmaceutics® is the key to optimize your drug product formulation and get ready for patient studies. Bringing CRO+CDMO services together reduces handoffs and allows reformulation to occur faster. Sponsors who choose Translational Pharmaceutics® have reached proof-of-concept studies an average 8-12 months earlier and up to $8-30M savings.

Have a formulation challenge? Don't go through another lengthy development cycle. Quotient Sciences Translational Pharmaceutics® uses emerging human data to guide development decisions and achieve an optimized drug product formulation, fast. Sponsors who choose Translational Pharmaceutics® see an average 19% improved success rate in reaching Phase 2 compared to conventional methods.

Don't let CRO+CDMO handoffs slow down your early development milestones. Quotient Sciences connects formulation, manufacturing and clinical testing through our integrated platform, Translational Pharmaceutics®. Compress development timelines, reduce risk and make better-informed decisions using emerging human data.

First-in-human trials are an opportunity to learn, adapt and make stronger development decisions. By integrating formulation, manufacturing and clinical testing, Quotient Sciences Translational Pharmaceutics® helps sponsors respond proactively to emerging human data and build a clearer path forward for their drug program. Sponsors who choose Translational Pharmaceutics® see an average 19% improved success rate in reaching Phase 2, compared to conventional methods.